Okay, let's tackle this question about monoclonal antibodies. First, I need to recall what monoclonal antibodies (mAbs) are. They're lab-made proteins designed to target specific antigens. The question is asking which statement is true about them.

The core concept here is their structure and function. Monoclonal antibodies are produced from a single type of B cell, hence "mono"clonal. They're used in various treatments, including cancer and autoimmune diseases, by targeting specific molecules.

Now, the correct answer is probably related to their specificity. Let's think about the options. If one option says they target a single antigen, that's correct. Another might mention they're derived from multiple B cells, which would be wrong. Another could be about their use in diagnostics, which is true but maybe not the best answer here. Another might talk about being part of the immune system, but they're synthetic.

The wrong options need to be addressed. For example, if an option states they are polyclonal, that's incorrect because monoclonal means one clone. If another says they are not used in therapy, that's wrong because they are widely used. Another might claim they have high cross-reactivity, but mAbs are known for their specificity, so that's false.

A clinical pearl is that mAbs are key in targeted therapies, like trastuzumab for HER2-positive breast cancer. Their specificity reduces off-target effects compared to traditional drugs.

Putting it all together, the correct answer should highlight their single antigen targeting and monoclonal origin. The explanation needs to clarify why other options are wrong, such as polyclonal vs. monoclonal, incorrect applications, or non-specificity.

**Core Concept**
Monoclonal antibodies (mAbs) are laboratory-produced proteins derived from a single B-cell clone, designed to bind to a specific antigen. They are used therapeutically to target disease-related molecules with high specificity, minimizing off-target effects.

**Why the Correct Answer is Right**
The correct statement is that monoclonal antibodies are **derived from a single B-cell clone** and recognize **one specific antigen epitope**. This is achieved through hybridoma technology or recombinant DNA methods. Their specificity arises from the uniform structure of their antigen-binding site, making them effective for targeted therapies like cancer (e.g., trastuzumab for HER2) or autoimmune diseases (e.g., adalimumab for TNF-α).

**Why Each Wrong Option is Incorrect**
**Option A:** Claims mAbs are "polyclonal" – incorrect, as polyclonal antibodies originate from multiple B-cell clones and recognize multiple epitopes.
**Option B:** States they are "naturally produced by the body" – false, as mAbs are synthetic, though modeled after natural antibodies.
**Option C:** Suggests they bind multiple antigens – wrong, as mAbs are engineered for single-antigen specificity.
**Option D:** Asserts they are "non-immunogenic" – incorrect, as mAbs (especially murine-derived) can trigger immune responses.

**Clinical Pearl / High-Yield Fact**
Remember: **"Mono = one"** – monoclonal antibodies target one antigen. Contrast with **polyclonal** (many antigens). Key mAbs include rituximab (CD20 in lymphoma

✓ Correct Answer: D. All